Reza Naghavi, MD
Internal Medicine · Rockville Centre, NYNPI 1841231545
Payments from drug & device makers
Across 119 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$387
- Novo Nordisk$259
- Amarin Pharma, Inc.$183
- AstraZeneca$180
- Inspire Medical Systems, Inc.$161
- Amgen$135
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 22 | $387 |
| Novo Nordisk | 13 | $259 |
| Amarin Pharma, Inc. | 9 | $183 |
| AstraZeneca | 10 | $180 |
| Inspire Medical Systems, Inc. | 2 | $161 |
| Amgen | 6 | $135 |
| Gilead | 1 | $113 |
| Exact Sciences | 5 | $104 |
| Novartis | 5 | $83 |
| Tempus AI, Inc | 3 | $72 |
| Shield Therapeutics Inc | 3 | $67 |
| Jazz Pharmaceuticals Inc. | 3 | $67 |
| Kowa Pharmaceuticals America, Inc. | 3 | $56 |
| Lilly USA, LLC | 3 | $55 |
| Boehringer Ingelheim | 3 | $51 |
| AbbVie(2 entities) | 3 | $51 |
| Astellas Pharma US Inc | 3 | $50 |
| Scilex Pharmaceuticals Inc. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Abbott | 2 | $45 |
| Renalytix AI, Inc. | 2 | $44 |
| Corcept Therapeutics | 2 | $43 |
| Phadia US Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $32 |
| Pfizer | 2 | $31 |
| Eisai Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| RGH Enterprises LLC | 1 | $20 |
| Seqirus USA Inc | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,541 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 170 | $178,825 |
| MounjaroTirzepatide | 89 | $106,913 |
| Metformin Er GastricMetformin Hcl | 74 | $90,738 |
| Naproxen Sodium CrNaproxen Sodium | 92 | $90,385 |
| EliquisApixaban | 52 | $75,400 |
| RybelsusSemaglutide | 39 | $55,550 |
| Diclofenac Sodium | 409 | $50,235 |
| Lidocaine | 435 | $46,467 |
| XareltoRivaroxaban | 32 | $37,456 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $33,432 |
| FarxigaDapagliflozin Propanediol | 28 | $31,500 |
| JanuviaSitagliptin Phosphate | 23 | $28,148 |
| Atovaquone | 51 | $27,471 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 46 | $26,846 |
| JardianceEmpagliflozin | 22 | $26,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $259 | $234,376209 claims |
| Lilly USA, LLCMounjaro, Trulicity | $55 | $127,722106 claims |
| PfizerEliquis | $31 | $75,40052 claims |
| GSKTrelegy Ellipta | $387 | $33,43252 claims |
| AstraZenecaFarxiga | $180 | $31,50028 claims |
| MerckJanuvia | $14 | $28,14823 claims |
| Boehringer IngelheimJardiance | $51 | $26,11922 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $10,71212 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $22 | $10,19276 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Rockville Centre
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.